

Scott E Strome

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7625517/publications.pdf>

Version: 2024-02-01

42
papers

7,469
citations

257450

24
h-index

265206

42
g-index

44
all docs

44
docs citations

44
times ranked

11739
citing authors

#	ARTICLE	IF	CITATIONS
1	Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks. <i>Cells</i> , 2019, 8, 1327.	4.1	59
2	The evolving role of immunoncology for the treatment of head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 62-69.	1.5	3
3	Is routine genetic testing warranted in head and neck paragangliomas?. <i>Laryngoscope</i> , 2019, 129, 1491-1493.	2.0	4
4	Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavity. <i>Head and Neck</i> , 2019, 41, 2514-2524.	2.0	22
5	NK cell expression of Tim-3: First impressions matter. <i>Immunobiology</i> , 2019, 224, 362-370.	1.9	38
6	A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity. <i>JCI Insight</i> , 2019, 4, .	5.0	19
7	What additional treatment is indicated for oral cavity cancer with isolated perineural invasion?. <i>Laryngoscope</i> , 2017, 127, 1965-1966.	2.0	2
8	Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease. <i>Journal of Autoimmunity</i> , 2017, 84, 97-108.	6.5	17
9	A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b. <i>Blood Advances</i> , 2017, 1, 504-515.	5.2	26
10	Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center. <i>Head and Neck</i> , 2016, 38, 564-572.	2.0	42
11	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. <i>Oral Oncology</i> , 2016, 61, 152-158.	1.5	48
12	Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease. <i>Journal of Immunology</i> , 2016, 196, 1165-1176.	0.8	10
13	Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional. <i>Cytokine</i> , 2015, 72, 48-57.	3.2	11
14	Impact of Detachment Methods on M2 Macrophage Phenotype and Function. <i>Journal of Immunological Methods</i> , 2015, 426, 56-61.	1.4	41
15	Fc fusion as a platform technology: potential for modulating immunogenicity. <i>Trends in Biotechnology</i> , 2015, 33, 27-34.	9.3	135
16	Immature Teratoma of the Maxillary Sinus. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 870.	2.2	5
17	The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in Fc γ R3 ^{hi} mice. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 947-958.	4.2	5
18	The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2014, 50, 627-632.	1.5	194

#	ARTICLE	IF	CITATIONS
19	Oropharyngeal cancer (OPC) and racial outcome disparities in squamous cell carcinoma of the head and neck (HNSCC): Ten-year experience at the University of Maryland Greenebaum Cancer Center (UMGCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6083-6083.	1.6	1
20	A phase I dose escalation trial of MAGE-A3 and HPV-16 specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2014, 32, e17014-e17014.	1.6	2
21	Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice. <i>Arthritis Research and Therapy</i> , 2012, 14, R192.	3.5	54
22	induction of mAGEA3 and HPV16 immunity by Trojan vaccines in patients with head and neck carcinoma. <i>Head and Neck</i> , 2012, 34, 1734-1746.	2.0	57
23	Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010. <i>Cancer Research</i> , 2011, 71, 3175-3181.	0.9	63
24	B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. <i>Blood</i> , 2010, 116, 1291-1298.	1.4	287
25	FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 997-1006.	4.2	108
26	Synthetic Peptide-Based Cancer Vaccines: Lessons Learned and Hurdles to Overcome. <i>Current Molecular Medicine</i> , 2009, 9, 683-693.	1.3	20
27	Fc-dependent expression of CD137 on human NK cells: insights into agonistic effects of anti-CD137 monoclonal antibodies. <i>Blood</i> , 2008, 112, 699-707.	1.4	102
28	A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects. <i>Oncologist</i> , 2007, 12, 1084-1095.	3.7	144
29	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 17174-17179.	7.1	723
30	Costimulation-based immunotherapy for head and neck cancer. <i>Current Treatment Options in Oncology</i> , 2004, 5, 27-33.	3.0	12
31	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. <i>Journal of Clinical Investigation</i> , 2003, 111, 363-370.	8.2	164
32	B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. <i>Cancer Research</i> , 2003, 63, 6501-5.	0.9	401
33	Reassessment of CD62L as a Marker of Pre-Effector T Cells in the Tumor Draining Lymph Nodes of Head and Neck Cancer Patients. <i>Otolaryngology - Head and Neck Surgery</i> , 2002, 126, 180-187.	1.9	0
34	Advanced larynx cancer. <i>Current Treatment Options in Oncology</i> , 2002, 3, 11-20.	3.0	8
35	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. <i>Nature Medicine</i> , 2002, 8, 793-800.	30.7	4,217
36	Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. <i>Clinical Cancer Research</i> , 2002, 8, 281-6.	7.0	11

#	ARTICLE	IF	CITATIONS
37	Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. <i>Cancer Research</i> , 2002, 62, 1884-9.	0.9	108
38	Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. <i>Clinical Cancer Research</i> , 2002, 8, 1093-100.	7.0	110
39	Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. <i>Head and Neck</i> , 2001, 23, 899-906.	2.0	92
40	Open trial of methotrexate as treatment for autoimmune hearing loss. <i>Arthritis and Rheumatism</i> , 2001, 45, 146-150.	6.7	50
41	Epstein-Barr Virus DNA Is Not Increased in Tonsillar Carcinoma. <i>Laryngoscope</i> , 2001, 111, 811-814.	2.0	10
42	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. , 0, .		1